Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7136730 | 0.80 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4122243 | 0.77 | SLC6A2 (0.81) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL10726904 | 0.76 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNH2TRPM8 | |
| SCHEMBL19501361 | 0.76 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4112198 | 0.76 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4115360 | 0.75 | SLC6A2 (0.72) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL17786117 | 0.75 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4112125 | 0.74 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL13543042 | 0.74 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL4114792 | 0.73 | SLC6A2 (0.84) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576105-B2 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20060106066-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | BAXTER ELLEN W | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106066-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | OPRD1, OPRK1, OPRM1 | SLC6A4 277/4885SLC6A2 860/4885SLC6A3 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.